An observational study in Atopic Dermatitis, sponsored by CorEvitas. Recruiting at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-08-26.
Sponsored by CorEvitas · Observational
This prospective, non-interventional research registry is designed to study the comparative effectiveness and comparative safety of approved treatments for patients with atopic dermatitis under the care of a licensed dermatologist or qualified physician extender. Secondary objectives include analyzing the epidemiology and natural history of the disease, its comorbidities, and current treatment practices.
Condition or disease :
Atopic Dermatitis
The objective of the CorEvitas Atopic Dermatitis (AD) Registry is to create a national cohort of patients with atopic dermatitis. Data collected will be used to extensively evaluate the effectiveness and safety of medications used to treat atopic dermatitis. This will be done through the standardized collection of patient-reported outcomes (PRO) and clinician-reported outcomes (ClinRO), and the prevalence and incidence of comorbidities and adverse events, medication utilization patterns, and patient productivity measures.
1,591 studies on the registry are indexed under Dermatitis, Atopic; 286 are open to participants now.
This study's planned enrollment of 10,000 is above the median of 150 across 282 observational studies indexed under Dermatitis, Atopic.
Browse Dermatitis, Atopic studies →CorEvitas is the lead sponsor of 28 studies on the registry; 21 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Patients are enrolled in the Atopic Dermatitis Registry during regularly scheduled office visits clinical encounters. Selected dermatologists are invited to participate as investigators in the Registry.
Inclusion Criteria Has been diagnosed with AD by a dermatologist or qualified dermatology provider.
2) Is at least 18 years of age or older and has attained the legal age for consent to procedures involved in the research, under the applicable law of the jurisdiction in which the research is being conducted.
3) Willing and able to provide consent for participation in the registry. 4) Willing and able to provide Personal Information (full legal name, sex, date of birth, home address zip/postal code, and email address OR phone number at a minimum) if required based on registry location and applicable laws and regulations. 5) Has been prescribed a new Enrollment Eligible Medication. A new therapy is a medication that the subject has never taken before.
Exclusion Criteria:
1)Is participating or planning to participate in a blinded clinical trial for an AD drug.
Follow-Up Criteria
Registry Follow-Up data collection should be done at the time of routine clinical encounters approximately every 6 months. Routine or standard of care clinical encounters may occur in between two registry visits, but the data collected in the Follow-Up forms should cover the time period since the last registry visit.
For planning purposes, each Follow-Up visit is anchored to the date of the last eligible registry visit. A Follow-Up visit is eligible for payment if 150 days have passed since the last visit submission. A Follow-Up visit is not eligible for payment if conducted less than 150 days since the last registry visits except when the EARLY Follow-Up visit Criteria are satisfied.
EARLY Follow-Up Criteria
A registry Follow-Up visit should be conducted whenever a patient is prescribed or receiving the first dose of a new Eligible Medication even if less than 150 days have passed since the last registry visit. When the EARLY Follow-Up criteria are met, the next anticipated registry visit is calculated from the date of the Early Follow-Up visit.
Pts presenting to enrolling sites across in North America and select European countries are invited to enroll if eligible
Other: Observational Non-Interventional Registry
Observational Non-Interventional Registry
AD epidemiology, presentation, natural history, management, and outcomes
The major clinical outcomes include an assessment of the epidemiology of Atopic Dermatitis; to better understand the presentation, natural history, management and outcomes.
Time frame: Through Study completion, an average of 10years
Percentage of patients with history of comorbidities
Time frame: at registry enrollment
Physician reported: validated Investigator Global Assessment for Atopic Dermatitis (vIGA-AD)
Score: 0-4, with high score indicating widespread of atopic dermatitis
Time frame: every 6 months for 10 years
Physician reported: Nail changes due to atopic dermatitis (graduated VAS)
Scale - 0 (Clear/Normal) to 100 (Severe Abnormalities). Lower numbers are for mild abnormalities in a few nails, higher numbers are for more severe changes in many nails
Time frame: every 6 months for 10 years
Physician reported: Atopic dermatitis body surface area (BSA)
Time frame: every 6 months for 10 years
Physician reported: Eczema Area and Severity Index (EASI) (calculated)
The severity of each sign will be graded on a scale of 0 to 3: (0) None, (1) Mild, (2) Moderate, (3) Severe.
Time frame: every 6 months for 10 years
Physician reported : SCORing Atopic Dermatitis index (SCORAD) (calculated)
The severity of each sign will be graded on a scale of 0 to 3: (0) None, (1) Mild, (2) Moderate, (3) Severe. For the Overall Score \[SCORAD\], select a lesion that that is representative of the body and score using the same severity scale
Time frame: every 6 months for 10 years
Patient reported: Patient global assessments of disease control and severity
This determines the progression \& severity of the disease
Time frame: every 6 months for 10 years
Patient reported: Patient Oriented Eczema Measure (POEM)
Time frame: every 6 months for 10 years
Patient reported: Peak pruritus (itch) NRS
Time frame: every 6 months for 10 years
Patient reported: Skin pain NRS
Time frame: every 6 months for 10 years
Patient reported: Fatigue NRS
Time frame: every 6 months for 10 years
Patient reported: Dermatology Life Quality Index (DLQI)
Time frame: every 6 months for 10 years
Patient reported: Work Productivity and Activity Impairment (WPAI)
Time frame: every 6 months for 10 years
Patient reported: Atopic dermatitis control tool (ADCT)
Time frame: every 6 months for 10 years
Patient reported: Itch triggers (PROMIS)
Time frame: every 6 months for 10 years
Patient reported: Sleeplessness and average pruritus (itch) NRS (SCORAD)
Time frame: 6 months for 10 years
Plan to share: No
No publications or documents are linked to this record.
Started Jul 2020 (actual). Primary completion is estimated for Dec 2100, 965 months after the start.
Of 96 non-industry observational studies under Dermatitis, Atopic, half reached primary completion within 61 months of starting (the median), counting those still running; a quarter within 19. This study's planned 965 months is above that.
Counting every sponsor, half of 170 studies reached it within 35 months; a quarter within 17.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
CorEvitas